Pharmacotherapy and efficacy of antihypoxants and antioxidants

Abstract

In clinical practice, antihypoxants, «deproteinized calf blood hemoderivatives », and an antioxidant, «ethylmethylhydroxypyridine succinate», are used in the treatment of cerebral ischemic stroke and transient attacks. The use of these drugs is pathophysiologically justified as it prevents neuronal damage, which is confirmed by the clinical guidelines «Ischemic Stroke and Transient Ischemic Attack in Adults», 2021. However, these drugs have not been proven effective. The purpose of the work: to study the expected effect of these drugs, based on pharmacodynamics and pharmacokinetics, as well as biochemical and physiological (pathophysiological) capabilities of the body.